抑制受体PVRIG在多发性骨髓瘤患者骨髓中主要表达，其阻断可增强t细胞接合者的免疫激活。

IF 2.5 4区医学 Q2 HEMATOLOGY

Experimental hematology Pub Date : 2024-12-16 DOI:10.1016/j.exphem.2024.104696

Masha Frenkel , Zoya Alteber , Ning Xu , Mingjie Li , Haiming Chen , Deborah Hayoun , Roy Zvi Granit , Gady Cojocaru , James Berenson , Eran Ophir

{"title":"抑制受体PVRIG在多发性骨髓瘤患者骨髓中主要表达，其阻断可增强t细胞接合者的免疫激活。","authors":"Masha Frenkel , Zoya Alteber , Ning Xu , Mingjie Li , Haiming Chen , Deborah Hayoun , Roy Zvi Granit , Gady Cojocaru , James Berenson , Eran Ophir","doi":"10.1016/j.exphem.2024.104696","DOIUrl":null,"url":null,"abstract":"<div><div>Therapeutic advances in treating patients with multiple myeloma (MM), including novel immunotherapies, have improved the disease control, but it remains incurable. Although traditional immune check point inhibitors have shown limited clinical benefit, targeting alternative immune-inhibitory pathways may offer a novel way to address relapsed disease. Blockade of the immune regulator TIGIT was shown to enhance antitumor immunity in preclinical MM models. Beyond TIGIT, the DNAM-1 axis includes the novel inhibitory receptor PVR related immunoglobulin (PVRIG). In this study we evaluated the expression of DNAM-1 axis receptors and the function of PVRIG in bone marrow of individuals with MM, specifically highlighting PVRIG blockade as a potential therapeutic opportunity in combination with bispecific T-cell engager (BiTE).</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"143 ","pages":"Article 104696"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation\",\"authors\":\"Masha Frenkel , Zoya Alteber , Ning Xu , Mingjie Li , Haiming Chen , Deborah Hayoun , Roy Zvi Granit , Gady Cojocaru , James Berenson , Eran Ophir\",\"doi\":\"10.1016/j.exphem.2024.104696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Therapeutic advances in treating patients with multiple myeloma (MM), including novel immunotherapies, have improved the disease control, but it remains incurable. Although traditional immune check point inhibitors have shown limited clinical benefit, targeting alternative immune-inhibitory pathways may offer a novel way to address relapsed disease. Blockade of the immune regulator TIGIT was shown to enhance antitumor immunity in preclinical MM models. Beyond TIGIT, the DNAM-1 axis includes the novel inhibitory receptor PVR related immunoglobulin (PVRIG). In this study we evaluated the expression of DNAM-1 axis receptors and the function of PVRIG in bone marrow of individuals with MM, specifically highlighting PVRIG blockade as a potential therapeutic opportunity in combination with bispecific T-cell engager (BiTE).</div></div>\",\"PeriodicalId\":12202,\"journal\":{\"name\":\"Experimental hematology\",\"volume\":\"143 \",\"pages\":\"Article 104696\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0301472X24005605\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301472X24005605","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

多发性骨髓瘤（MM）的治疗进展，包括新的免疫疗法，已经改善了疾病的控制，但它仍然是无法治愈的。尽管传统的免疫检查点抑制剂显示出有限的临床益处，但靶向替代免疫抑制途径可能为治疗复发性疾病提供一种新的方法。在临床前MM模型中，阻断免疫调节因子TIGIT可增强抗肿瘤免疫。除了TIGIT， DNAM-1轴还包括新的抑制受体PVRIG。在这项研究中，我们评估了MM患者骨髓中DNAM-1轴受体的表达和PVRIG的功能，特别强调PVRIG阻断与双特异性t细胞接合剂（BiTE）联合使用是一种潜在的治疗机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation

Therapeutic advances in treating patients with multiple myeloma (MM), including novel immunotherapies, have improved the disease control, but it remains incurable. Although traditional immune check point inhibitors have shown limited clinical benefit, targeting alternative immune-inhibitory pathways may offer a novel way to address relapsed disease. Blockade of the immune regulator TIGIT was shown to enhance antitumor immunity in preclinical MM models. Beyond TIGIT, the DNAM-1 axis includes the novel inhibitory receptor PVR related immunoglobulin (PVRIG). In this study we evaluated the expression of DNAM-1 axis receptors and the function of PVRIG in bone marrow of individuals with MM, specifically highlighting PVRIG blockade as a potential therapeutic opportunity in combination with bispecific T-cell engager (BiTE).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Experimental hematology 医学-血液学

CiteScore

5.30

自引率

0.00%

发文量

审稿时长

58 days

期刊介绍： Experimental Hematology publishes new findings, methodologies, reviews and perspectives in all areas of hematology and immune cell formation on a monthly basis that may include Special Issues on particular topics of current interest. The overall goal is to report new insights into how normal blood cells are produced, how their production is normally regulated, mechanisms that contribute to hematological diseases and new approaches to their treatment. Specific topics may include relevant developmental and aging processes, stem cell biology, analyses of intrinsic and extrinsic regulatory mechanisms, in vitro behavior of primary cells, clonal tracking, molecular and omics analyses, metabolism, epigenetics, bioengineering approaches, studies in model organisms, novel clinical observations, transplantation biology and new therapeutic avenues.